Mongersen and SMAD-7 Inhibition, Not a Lucky 7 for Patients With IBD: When Trial Design Is as Important as Disease Therapy.

Bewtra, Meenakshi

Mongersen and SMAD-7 Inhibition, Not a Lucky 7 for Patients With IBD: When Trial Design Is as Important as Disease Therapy. [electronic resource] - The American journal of gastroenterology 05 2020 - 687-688 p. digital

Publication Type: Journal Article

1572-0241

10.14309/ajg.0000000000000564 doi


Crohn Disease
Humans
Oligonucleotides
Remission Induction